CD63-positive extracellular vesicles are potential diagnostic biomarkers of pancreatic ductal adenocarcinoma

BMC Gastroenterology

Table 2 Summary of ROC analysis

	AUC (95% CI)	Threshold	Specificity	Sensitivity	p-value^a (vs CA19-9)
All stage
CA19-9	0.842 (0.755–0.930)	11.7	0.769	0.846
CD63⁺-EVs	0.846 (0.752–0.941)	0.016	0.846	0.821	0.945
CD41⁺-EVs	0.678 (0.552–0.804)	0.079	0.744	0.718	0.0290
CD61⁺-EVs	0.652 (0.527–0.776)	0.045	0.641	0.718	0.00932
CD63⁺-EVs × CA19-9	0.903 (0.823–0.984)	0.136	0.872	0.897	0.124
Early stage (I–II)
CA19-9	0.814 (0.699–0.929)	11.7	0.769	0.87
CD63⁺-EVs	0.858 (0.745–0.971)	0.011	0.0769	0.913	0.557
CD41⁺-EVs	0.685 (0.529–0.84)	0.079	0.744	0.738	0.197
CD61⁺-EVs	0.657 (0.51–0.804)	0.045	0.641	0.739	0.0992
CD63⁺-EVs × CA19-9	0.906 (0.802–1)	0.264	0.923	0.87	0.0330
Late-stage (III–IV)
CA19-9	0.883 (0.773–0.993)	36	0.949	0.75
CD63⁺-EVs	0.83 (0.689–0.972)	0.018	0.846	0.812	0.517
CD41⁺-EVs	0.668 (0.495–0.842)	0.081	0.744	0.625	0.00769
CD61⁺-EVs	0.644 (0.468–0.82)	0.048	0.667	0.688	0.00236
CD63⁺-EVs × CA19-9	0.899 (0.773–1)	0.136	0.872	0.875	0.809

ROC: Receiver operating characteristic, AUC: area under curve, CI: confidence interval
^ap-value in DeLong's test

ISSN: 1471-230X